ANSWER: C

Rationale:

This question asked you to explain the mechanism of ergotamine's coronary artery disease contraindication and identify an appropriate alternative with its correct pharmacological caveat. Option C is correct. Ergotamine's non-selective multi-receptor vasoconstriction is the mechanistic basis of its absolute contraindication in CAD. Unlike triptans, ergotamine simultaneously activates alpha-1 adrenergic receptors (Gq/PLC/IP3/calcium), alpha-2 adrenergic receptors (postsynaptic contractile drive), and 5-HT2A receptors (Gq/PLC/IP3/calcium) on coronary arterial smooth muscle, in addition to its 5-HT1B agonism. This multi-receptor contractile drive in coronary arteries already narrowed by fixed atherosclerotic plaque can precipitate vasospasm sufficient to produce unstable angina or myocardial infarction. Triptans are pharmacologically preferred because their selectivity for 5-HT1B/1D receptors eliminates the adrenergic and 5-HT2A coronary vasoconstrictive components, but they are not without coronary risk — 5-HT1B receptors are expressed in coronary smooth muscle, and triptan-induced coronary vasoconstriction has been documented clinically. Therefore triptans also carry an absolute contraindication in CAD. Gepants (rimegepant, ubrogepant) — CGRP receptor antagonists — produce antimigraine efficacy without any vasoconstrictive mechanism, making them the safest acute option in patients with established cardiovascular disease.

• Option A: Option A is incorrect. Ergotamine does not act through dopamine D2 agonism to produce coronary vasodilation via coronary steal; its cardiovascular risk is mediated by alpha-adrenergic and serotonergic vasoconstrictive receptor activation, not dopaminergic vasodilation. Methysergide is not safe in CAD patients and is no longer in widespread clinical use; it carries its own cardiovascular risks.
• Option B: Option B is incorrect. Ergotamine is a reversible partial agonist, not an irreversible alkylating agent; it does not form covalent bonds with alpha-1 ARs. Calcium channel blockers taken at migraine onset are not established acute migraine treatments that work by displacing ergotamine from coronary smooth muscle calcium channels.
• Option D: Option D is incorrect. Metoprolol is a beta-1 adrenergic antagonist, not a CYP2D6 inhibitor relevant to ergotamine metabolism; ergotamine is metabolized primarily by CYP3A4, not CYP2D6. The described pharmacokinetic mechanism does not account for ergotamine's CAD contraindication, which is pharmacodynamic in origin.
• Option E: Option E is incorrect. While ergotamine and triptans both activate 5-HT1B receptors in coronary vasculature, their coronary risk profiles are not identical; ergotamine's additional alpha-adrenergic and 5-HT2A activation makes its coronary vasoconstrictive drive substantially greater and less selective than that of triptans. The characterization of identical coronary risk between the two classes overstates the triptan risk relative to the established pharmacological distinction.

ANSWER: A

Rationale:

This question asked you to explain why the pregnant uterus at 34 weeks is dramatically more sensitive to ergonovine and identify the receptor-level mechanism responsible for fetal compromise. Option A is correct. The mechanism of ergot alkaloid hypersensitivity in the pregnant uterus is estrogen-driven upregulation of myometrial 5-HT2A receptors. Estrogen, present at markedly elevated concentrations throughout pregnancy and peaking in the third trimester, increases both the surface expression of myometrial 5-HT2A receptors and the efficiency of their Gq protein coupling. Because ergonovine activates myometrial smooth muscle through both alpha-1 adrenergic receptors and 5-HT2A receptors, and because the 5-HT2A component is specifically amplified by estrogen-driven upregulation, the same ergonovine dose that produces modest vasoconstriction in a non-pregnant patient can trigger intense, sustained, tetanic uterine contraction in a 34-week pregnant patient. Unlike oxytocin's physiological phasic contraction pattern — which produces rhythmic waves with relaxation intervals allowing uteroplacental perfusion recovery — ergot-induced contraction is tonic and non-rhythmic. The sustained tonic contraction continuously compresses the placental vascular bed, eliminating the relaxation-phase perfusion that provides fetal oxygenation. The resulting progressive fetal hypoxia manifests as late decelerations on the fetal heart rate tracing — a pattern caused by uteroplacental insufficiency. This is entirely a pharmacodynamic phenomenon driven by receptor upregulation, not a pharmacokinetic concentration change.

• Option B: Option B is incorrect. hCG does not cross-react with myometrial alpha-1 adrenergic receptors; hCG acts through its own Gs-coupled LH/hCG receptor on the corpus luteum and other tissues. hCG concentrations peak in the first trimester, not at 34 weeks, and fetal adrenal alpha-1 AR activation by transplacentally transferred ergot alkaloid is not the established mechanism of fetal heart rate changes with maternal ergonovine administration.
• Option C: Option C is incorrect. Ergonovine does not cross-react with oxytocin receptors; ergonovine and oxytocin act through entirely separate receptor systems — alpha-adrenergic and serotonergic for ergonovine, versus Gq-coupled oxytocin receptors for oxytocin. The mechanism described in Option C invents a receptor cross-reactivity that does not reflect established pharmacology.
• Option D: Option D is incorrect. The increased sensitivity of the pregnant uterus to ergot alkaloids is a pharmacodynamic phenomenon driven by receptor upregulation, not a pharmacokinetic gradient of local uterine drug concentration; pharmacokinetic models do not support a 10-fold uterine concentration advantage relative to systemic levels.
• Option E: Option E is incorrect. Progesterone generally maintains uterine quiescence during pregnancy and its withdrawal at term is associated with the onset of labor — progesterone does not sensitize alpha-1 ARs to produce greater uterotonic response. The described mechanism inverts progesterone's established role in myometrial tone regulation, and the claim that ergot sensitivity is maximal at term when progesterone is highest contradicts the known physiology of progesterone withdrawal triggering labor.

ANSWER: E

Rationale:

This question asked you to identify the mechanism of methylergonovine-induced hypertension, classify its clinical significance in this scenario, and outline appropriate management. Option E is correct. Methylergonovine produces uterotonic contraction through combined alpha-1 adrenergic and 5-HT2A receptor activation on myometrial smooth muscle, but the alpha-adrenergic component is not confined to the uterus. Systemic alpha-1 adrenergic receptor activation increases peripheral vascular resistance, raising both systolic and diastolic blood pressure. In normotensive postpartum patients this pressor response is typically modest and transient. In this patient, however, the rise to 168/112 mmHg with a severe headache represents a hypertensive urgency — a degree of blood pressure elevation that carries risk of target organ injury, particularly hypertensive encephalopathy or intracranial hemorrhage in the context of recent delivery where cerebrovascular autoregulation may be impaired. The severe headache is a warning symptom that must be taken seriously. Appropriate management includes immediately withholding any further methylergonovine doses, administering intravenous antihypertensive therapy — hydralazine (a direct arteriolar vasodilator) or labetalol (a combined alpha-1 and beta-adrenergic blocker) are standard first-line agents in the postpartum setting — and evaluating the headache for signs of hypertensive encephalopathy or hemorrhage.

• Option A: Option A is incorrect. While the pressor response to methylergonovine is a pharmacologically expected consequence of its mechanism, a BP of 168/112 mmHg with a severe headache in a recently delivered patient is not an acceptable expected outcome that requires no treatment; this degree of hypertension with neurological symptoms requires active management and carries risk of serious complications.
• Option B: Option B is incorrect. The hypertension is not caused by presynaptic alpha-2 autoreceptor activation producing a rebound sympathetic surge; this mechanism inverts the pharmacology. Methylergonovine's pressor effect is a direct consequence of postsynaptic alpha-1 AR vasoconstriction, not a rebound phenomenon. Continuing methylergonovine while treating with phentolamine would be inappropriate management of this presentation.
• Option C: Option C is incorrect. Methylergonovine does not produce its cardiovascular effects through D2 receptor agonism in the nucleus tractus solitarius; its pressor effect is mediated by peripheral alpha-1 adrenergic vasoconstriction. Haloperidol has no established role in managing methylergonovine-induced hypertension.
• Option D: Option D is incorrect. Selective renal afferent arteriolar constriction by 5-HT1B agonism triggering renin release is not the established mechanism of methylergonovine's acute pressor effect; the onset of renin-angiotensin cascade hypertension is too slow (hours to days) to account for a blood pressure rise within 12 minutes of drug administration. ACE inhibitors are contraindicated in the postpartum breastfeeding period and are not appropriate acute antihypertensives in this setting.

ANSWER: D

Rationale:

This question asked you to identify the pharmacological cause of cabergoline-associated valvulopathy, explain its dose-dependence, and determine appropriate management. Option D is correct. Cabergoline-associated cardiac valvulopathy is caused by agonism at 5-HT2B receptors on cardiac valve interstitial fibroblasts. 5-HT2B receptors are Gq-coupled; their activation stimulates fibroblast proliferation and collagen synthesis through PLC/IP3/calcium and downstream transcriptional mechanisms, producing progressive fibrous thickening of valve leaflets and subvalvular structures — most commonly affecting the tricuspid and mitral valves. This mechanism is the same as that responsible for cardiac valvulopathy from fenfluramine (withdrawn from the market) and, to a lesser extent, high-dose ergotamine. The dose-dependence is pharmacologically explicable: at the substantially lower plasma concentrations achieved with hyperprolactinemia dosing (0.25–1 mg twice weekly), cabergoline does not reliably occupy cardiac valve 5-HT2B receptors at concentrations sufficient to drive fibroblast activation. At Parkinson's disease doses (2–6 mg daily), plasma concentrations reach the threshold for meaningful 5-HT2B receptor occupancy on valve fibroblasts, and with years of sustained exposure, progressive fibrosis accumulates. Management requires discontinuation of cabergoline — the fibrotic process may partially regress after drug withdrawal — and substitution with a non-ergot dopamine agonist. Pramipexole and ropinirole are D2/D3 selective agonists that do not possess 5-HT2B agonist activity and are the standard replacements in this clinical situation.

• Option A: Option A is incorrect. Cabergoline's valvulopathy mechanism is 5-HT2B receptor agonism on fibroblasts, not alpha-1 adrenergic agonism; alpha-1 AR signaling does not drive fibroblast collagen synthesis in the manner described. Bromocriptine has alpha-adrenergic antagonist properties but shares the ergot class structural features and is not the recommended replacement; non-ergot agents are preferred.
• Option B: Option B is incorrect. D2 receptor agonism on valve endothelial cells suppressing prostacyclin is not the established mechanism of cabergoline valvulopathy; the mechanism is 5-HT2B-mediated fibroblast activation, not endothelial prostanoid imbalance. Not all dopaminergic ergot alkaloids share this liability; bromocriptine lacks significant 5-HT2B agonist activity at therapeutic doses and has a substantially lower valvulopathy risk than cabergoline.
• Option C: Option C is incorrect. Cabergoline has a well-established and pharmacologically characterized association with cardiac valvulopathy at Parkinson's disease doses, supported by multiple prospective echocardiographic studies and mechanistic data. Attributing the valvulopathy to idiopathic Parkinson's disease-related cardiac autonomic dysfunction ignores an established drug-induced cause that requires medication change.
• Option E: Option E is incorrect. Cabergoline does not produce an accumulating ergotamine-like CYP3A4 metabolite responsible for its valvulopathy; the mechanism is the parent compound's 5-HT2B agonism, not a metabolite-driven vasospastic process. Rifampicin induction to accelerate metabolite clearance has no established role in managing cabergoline-associated valvulopathy, and continuing cabergoline at any dose while the valve damage progresses would be inappropriate.

ANSWER: B

Rationale:

This question asked you to characterize the pharmacokinetic interaction between itraconazole and DHE, predict the clinical outcome, and determine appropriate management. Option B is correct. Itraconazole is a potent, sustained CYP3A4 inhibitor used systemically at high doses for dermatophyte infections including onychomycosis. DHE, like ergotamine, undergoes extensive first-pass hepatic metabolism by CYP3A4, which is the primary mechanism limiting its systemic bioavailability. When itraconazole markedly inhibits CYP3A4, DHE's first-pass extraction is substantially reduced, dramatically elevating systemic plasma DHE concentrations from the same administered dose. The resulting high plasma concentrations drive simultaneous activation of alpha-adrenergic and serotonergic receptors across peripheral vascular beds — including coronary and digital arteries — producing multi-vascular vasospasm identical to that seen with any CYP3A4 inhibitor-ergot alkaloid co-administration. This interaction is listed as an absolute contraindication in DHE's prescribing information; the drug combination is not safely manageable with dose reduction or monitoring because the magnitude of itraconazole's CYP3A4 inhibition is too great to compensate pharmacokinetically. The correct recommendation is to withhold DHE for the duration of the 12-week itraconazole course and use a suitable alternative — triptans are appropriate if not otherwise contraindicated, since they are not CYP3A4 substrates to a clinically significant degree and do not carry the same interaction risk with azole antifungals.

• Option A: Option A is incorrect. Itraconazole is a CYP3A4 inhibitor, not a P-glycoprotein inducer; its primary drug interaction mechanism relevant to DHE involves hepatic metabolic inhibition, not efflux transporter induction at the nasal mucosa. Switching to oral DHE would not mitigate a CYP3A4-mediated first-pass inhibition interaction, as oral DHE is also subject to hepatic CYP3A4 metabolism.
• Option C: Option C is incorrect. Itraconazole is a CYP3A4 inhibitor, not an inducer; it does not activate the pregnane X receptor to increase CYP3A4 expression. Framing the interaction as enzyme induction requiring dose escalation inverts the correct pharmacology and would lead to dangerous DHE toxicity if acted upon.
• Option D: Option D is incorrect. Itraconazole's interaction with DHE is not mediated by renal tubular secretion inhibition of DHE metabolites; DHE is hepatically metabolized, not renally excreted to a clinically significant degree. The described mechanism is fictitious and the conclusion that the interaction is clinically insignificant is incorrect and dangerous.
• Option E: Option E is incorrect. Itraconazole's antifungal mechanism — inhibition of fungal CYP51 (lanosterol 14α-demethylase) in ergosterol synthesis — does not cross-react with the ergoline ring of DHE; the ergoline pharmacophore and fungal ergosterol biosynthetic intermediates are structurally unrelated in terms of enzyme interactions. Itraconazole does not reduce DHE absorption through an ergoline-ergosterol structural cross-reactivity.

ANSWER: C

Rationale:

This question asked you to diagnose medication overuse headache from ergotamine, explain the two pharmacological mechanisms responsible, and outline correct management. Option C is correct. The clinical picture is the pathognomonic presentation of medication overuse headache (MOH): a patient with episodic migraine who has used an acute treatment more than the recommended frequency limit (ergotamine is limited to no more than 2 days per week) for more than 3 months, who now has markedly increased headache frequency, a qualitative change in headache character to a dull bilateral pressure type distinct from the original migraine, and a predictable morning withdrawal pattern — headaches that occur when overnight plasma concentrations fall and are promptly relieved by the next dose. Two concurrent pharmacological mechanisms drive this transformation. Central sensitization: chronic sustained 5-HT1B/1D partial agonism at central trigeminal pain processing centers produces neuroplastic changes that lower nociceptive thresholds, impair descending pain inhibitory pathways, and create a state of persistent pain vulnerability. Peripheral receptor adaptation: chronic ergotamine exposure produces compensatory adaptations in 5-HT1B/1D receptor expression and coupling that create physiological dependence — the adapted receptor state requires ongoing partial agonist exposure to maintain baseline function, and withdrawal of that exposure (overnight, due to ergotamine's 2-hour half-life) produces the withdrawal headache that is promptly relieved by the next morning dose. Management requires ergotamine discontinuation. The MOH cycle cannot be broken while the causative drug is continued. The expected worsening during the first 1–2 weeks of withdrawal should be anticipated and managed with bridging therapy. A preventive agent should be initiated once the withdrawal phase has passed.

• Option A: Option A is incorrect. Natural disease progression does not explain this pattern; the temporal correlation between the onset of frequent ergotamine use and the development of daily headaches, combined with the pharmacologically characteristic morning withdrawal pattern, points to MOH as the diagnosis. Continuing ergotamine and adding a preventive agent without addressing the overuse perpetuates the MOH cycle.
• Option B: Option B is incorrect. Chronic low-grade vasospastic headache from sustained meningeal vasoconstriction is not the established mechanism of ergotamine-associated headache transformation; MOH is mediated by central sensitization and receptor adaptation, not ongoing vascular ischemia. Adding a calcium channel blocker while continuing ergotamine does not address the MOH cycle.
• Option D: Option D is incorrect. Dose escalation of ergotamine is the opposite of correct management; increasing the frequency and dose of the causative agent deepens the MOH cycle and worsens the condition. Receptor downregulation requiring dose escalation is not the established pharmacological framework for MOH.
• Option E: Option E is incorrect. Extending ergotamine to a three-times-daily preventive schedule would convert the patient from intermittent overuse to continuous daily overuse, catastrophically worsening the MOH rather than treating it; the concept of pharmacokinetic rebound vasodilation driving morning headaches is not the established mechanism of MOH, which is driven by central sensitization and receptor adaptation.

ANSWER: A

Rationale:

This question asked you to explain why phentolamine alone is pharmacologically insufficient for ergot vasospasm, identify the mechanisms sustaining vasospasm despite undetectable plasma drug, and define the correct treatment duration target. Option A is correct. Ergot vasospasm involves simultaneous activation of multiple receptor pathways that all converge on smooth muscle contraction: alpha-1 adrenergic (Gq/PLC/IP3/calcium), alpha-2 adrenergic postsynaptic, 5-HT1B (Gi-coupled but contractile downstream), and 5-HT2A (Gq/PLC/IP3/calcium, independent contractile drive). Phentolamine is a non-selective alpha-1 and alpha-2 adrenergic receptor antagonist; it blocks the adrenergic contractile drives but leaves the 5-HT2A-mediated contractile drive active. Because all contractile mechanisms are simultaneously engaged, blocking only one receptor family produces partial relief at best. Downstream vasodilators — nitroprusside (NO/cGMP/PKG) and prostaglandin E1 (EP receptor/Gs/cAMP/PKA) — override all receptor-mediated contractile signals simultaneously, regardless of which receptors are occupied. Three mechanisms account for vasospasm persisting at 6 hours despite undetectable plasma ergotamine: first, slow receptor dissociation kinetics mean that receptor-bound ergotamine maintains signaling at concentrations below the assay detection threshold; second, once calcium influx through voltage-gated L-type channels is established, contraction becomes self-sustaining independent of receptor occupancy; third, active vasoconstrictive metabolites including the O-demethylated metabolite retain pharmacological activity. The treatment duration target must be the pharmacodynamic endpoint: documented restoration of arterial flow by Doppler, return of palpable pulse, and normalization of skin perfusion — not drug elimination, which has already occurred.

• Option B: Option B is incorrect. Ergotamine does not form semi-covalent bonds with alpha-1 ARs after prolonged occupancy; it is a reversible partial agonist throughout its receptor interaction. Phenoxybenzamine is an irreversible alkylating agent, not the appropriate treatment for ergot vasospasm. Waiting for new receptor synthesis would result in gangrene.
• Option C: Option C is incorrect. Endothelin-1 release from endothelium via 5-HT3 receptor activation is not the established mechanism of sustained ergot vasospasm; ergot vasospasm is mediated by direct smooth muscle receptor activation. 5-HT3 receptors are ligand-gated ion channels primarily expressed in the gastrointestinal tract and CNS, not the primary mediators of sustained peripheral vasospasm in this setting.
• Option D: Option D is incorrect. Phentolamine is not sufficient monotherapy; the 5-HT2A component does not self-resolve within 2 hours, and undetectable plasma ergotamine does not indicate that all pharmacodynamic effects have terminated — the three persistence mechanisms detailed in Option A account for ongoing vasospasm. Concluding that persistent vasospasm with undetectable drug represents non-pharmacological ischemia requiring surgery would result in inappropriate operative management when pharmacological therapy remains indicated.
• Option E: Option E is incorrect. Ergotamine does not activate natriuretic peptide receptors; this receptor pathway is not part of established ergot vasospasm pharmacology, and atrial natriuretic peptide infusion has no established role in ergot vasospasm management.

ANSWER: D

Rationale:

This question asked you to identify ergot-induced mesenteric artery vasospasm as the cause of ischemic colitis in the setting of a CYP3A4 drug interaction, explain the mechanism, and determine management. Option D is correct. This presentation is a recognized complication of ergot alkaloid toxicity — mesenteric artery vasospasm producing colonic ischemia. The mesenteric vasculature, like coronary and digital arteries, expresses alpha-1 adrenergic, alpha-2 adrenergic, and 5-HT2A receptors, making it susceptible to ergot-induced vasospasm when ergot plasma concentrations reach toxic levels. The precipitating mechanism is the CYP3A4 interaction: clarithromycin is a potent CYP3A4 inhibitor that eliminates ergotamine's first-pass hepatic extraction, dramatically elevating systemic plasma ergotamine concentrations from a dose that was previously well tolerated. The resulting multi-receptor vasoconstrictive activation in mesenteric arteries reduces colonic blood flow, producing the mucosal ischemia manifest as bloody diarrhea and the CT findings of wall thickening with thumbprinting. Management requires immediate discontinuation of both ergotamine and clarithromycin (an appropriate antibiotic substitute should be selected from a non-CYP3A4-inhibiting class), intravenous vasodilator therapy — nitroprusside or prostaglandin E1 acting downstream of receptor activation — supportive care with bowel rest and nasogastric decompression, and close monitoring for bowel infarction requiring surgical intervention. This interaction is listed as an absolute contraindication in ergotamine's prescribing information.

• Option A: Option A is incorrect. While clarithromycin is associated with Clostridioides difficile colitis, the CT findings of circumferential thickening with thumbprinting in the sigmoid and descending colon in the context of a clarithromycin-ergotamine interaction are characteristic of ischemic colitis from vascular insufficiency, not C. difficile pseudomembranous colitis, which typically produces pancolonic or right-sided predominant changes. Continuing ergotamine in this setting would perpetuate the vasospasm.
• Option B: Option B is incorrect. Ergotamine does not produce ischemic colitis through a dose-independent cytotoxic sulfoxide metabolite accumulated in mesenteric veins; the mechanism of ergot-induced mesenteric ischemia is arterial vasospasm from receptor-mediated smooth muscle contraction, not direct mucosal cytotoxicity.
• Option C: Option C is incorrect. Clarithromycin does not produce mesenteric vasoconstriction through eNOS inhibition; this is not an established mechanism of clarithromycin's pharmacology. Clarithromycin's role in this case is as a CYP3A4 inhibitor that elevates ergotamine concentrations, not as a direct vasoconstrictor.
• Option E: Option E is incorrect. Colonic mucosal prostaglandin E2 depletion from ergotamine's 5-HT2A partial agonism on mast cells is not the established mechanism of ergot-induced colonic ischemia; the mechanism is arterial vasospasm from multi-receptor activation at toxic plasma concentrations. Clarithromycin's CYP3A4 inhibition is a well-established and clinically dangerous pharmacokinetic interaction with ergotamine, not a pharmacologically neutral co-administration as this option incorrectly claims.

ANSWER: E

Rationale:

This question asked you to explain the mechanism of methylergonovine's pressor effect, identify the most urgent clinical concern raised by the neurological symptoms, and outline immediate management priorities. Option E is correct. Methylergonovine produces uterotonic contraction through alpha-1 adrenergic and 5-HT2A receptor activation, but alpha-adrenergic activity is not confined to the myometrium. Systemic alpha-1 AR activation increases peripheral vascular resistance, raising blood pressure. Even in a previously normotensive patient, this pressor effect can be substantial. A BP of 172/106 mmHg with severe headache and transient visual blurring in the peripartum period is a medical emergency. The neurological symptoms — severe headache and visual disturbance — in the context of acute severe hypertension are warning signs of hypertensive encephalopathy or posterior reversible encephalopathy syndrome (PRES), a condition in which breakthrough hyperperfusion from failed cerebrovascular autoregulation produces cerebral edema predominantly in the posterior cerebral regions, causing headache, visual disturbances, seizures, and altered consciousness. PRES has a particular predisposition for the peripartum period because normal vascular autoregulation may be impaired after delivery. Immediate management priorities are: withhold any further methylergonovine, initiate IV antihypertensive therapy targeting BP below 160/110 mmHg (labetalol is preferred in the postpartum period for its combined alpha and beta blockade; hydralazine is an alternative), urgent neurological assessment, and brain MRI if neurological symptoms persist. The uterine hemorrhage requires alternative management — further oxytocin, carboprost, or misoprostol — as methylergonovine is now contraindicated in this patient.

• Option A: Option A is incorrect. Oxytocin receptor downregulation does not increase vascular sensitivity to methylergonovine; oxytocin receptors and adrenergic receptors are distinct receptor populations. Increasing oxytocin infusion to competitively limit methylergonovine's vascular access has no pharmacological basis and would not mitigate the hypertensive emergency.
• Option B: Option B is incorrect. A BP of 172/106 mmHg with severe headache and visual blurring in the peripartum period is not an acceptable expected outcome requiring no treatment; this represents a potential hypertensive emergency with serious risk of intracranial hemorrhage, stroke, or PRES. Attributing these symptoms to pain from uterine contraction and withholding treatment could have catastrophic consequences.
• Option C: Option C is incorrect. While cerebrovascular constriction may contribute to the clinical picture, the primary mechanism of methylergonovine's blood pressure elevation is systemic peripheral vascular resistance increase from alpha-adrenergic vasoconstriction, not selective posterior cerebral artery 5-HT2A constriction. Cyproheptadine is not established as the treatment for methylergonovine-induced hypertension; IV labetalol or hydralazine are the standard agents.
• Option D: Option D is incorrect. This presentation does not represent serotonin syndrome; serotonin syndrome requires excessive serotonergic activity across multiple receptor levels and presents with a triad of neuromuscular abnormalities (clonus, hyperreflexia, tremor), autonomic instability, and altered mental status — not acute severe hypertension with focal visual symptoms. Methylergonovine can cause hypertension through its adrenergic mechanism without producing serotonin syndrome.

ANSWER: B

Rationale:

This question asked you to explain the pharmacological basis for DHE's broader contraindication profile relative to sumatriptan, identifying the receptor activities responsible for each drug's efficacy and additional risks. Option B is correct. Both DHE and sumatriptan share the antimigraine receptor mechanisms that are clinically essential: 5-HT1B receptor agonism on cranial arterial smooth muscle (particularly dural and pial arteries) producing vasoconstriction of distended meningeal vessels, and 5-HT1D receptor agonism at trigeminal sensory nerve terminals inhibiting vesicular release of CGRP and other vasoactive neuropeptides. These shared mechanisms account for their broadly similar clinical efficacy in aborting migraine attacks. However, DHE's receptor profile extends substantially beyond 5-HT1B/1D selectivity. DHE additionally activates alpha-1 adrenergic receptors (Gq/PLC/IP3/calcium, peripheral vasoconstriction), alpha-2 adrenergic receptors (postsynaptic contractile drive in some vascular beds), and 5-HT2A receptors (Gq-coupled, additive vasoconstriction in peripheral and coronary vessels). These additional receptor activities produce vasoconstrictive drive in peripheral vascular beds that triptans, acting only through 5-HT1B/1D, do not engage to the same degree. The resulting peripheral and coronary vasoconstrictive profile mandates absolute contraindications in patients with peripheral vascular disease, established coronary artery disease, cerebrovascular disease, and Raynaud's phenomenon, and requires cardiovascular evaluation before use — contraindications that arise from a broader receptor footprint than sumatriptan's.

• Option A: Option A is incorrect. While the CYP3A4 pharmacokinetic interaction is a clinically important consideration for DHE, it is not the pharmacological basis for DHE's broader contraindication profile relative to sumatriptan; the contraindications arise from DHE's multi-receptor vasoconstrictive pharmacodynamics, not from CYP3A4 metabolism differences. Sumatriptan has its own prescribing restrictions including cardiovascular contraindications based on its 5-HT1B coronary activity.
• Option C: Option C is incorrect. DHE and sumatriptan are not pharmacologically identical at all relevant receptors; DHE's additional alpha-adrenergic and 5-HT2A activities are genuine pharmacological differences with genuine clinical consequences, not regulatory artifacts from a less sophisticated era.
• Option D: Option D is incorrect. DHE's additional cardiovascular risk is not attributable to D2 agonism producing coronary steal vasodilation; DHE's cardiovascular risk is from alpha-adrenergic and 5-HT2A-mediated peripheral and coronary vasoconstriction, which is the opposite of vasodilation.
• Option E: Option E is incorrect. DHE's broader contraindication profile is intrinsic to the drug's own receptor pharmacology and is not a statistical artifact from antiemetic co-administration requirements. The contraindications are based on DHE's direct vascular receptor activities, not on properties of metoclopramide or other co-administered antiemetics.

ANSWER: D

Rationale:

This question asked you to identify the mechanism of methysergide-induced retroperitoneal fibrosis, explain the rationale for drug holidays, and name currently preferred prophylactic alternatives. Option D is correct. Methysergide's fibrotic complications — retroperitoneal fibrosis, pleuropulmonary fibrosis, and cardiac valvular fibrosis — are mediated by 5-HT2B receptor agonism by methylergometrine, the pharmacologically active metabolite formed by hepatic N-demethylation of methysergide. 5-HT2B receptors on fibroblasts are Gq-coupled; their sustained activation drives fibroblast proliferation and collagen deposition through PLC/IP3/calcium signaling and downstream transcriptional pathways including TGF-beta and connective tissue growth factor activation. With continuous methysergide use, progressive collagen accumulation in the retroperitoneum produces the dense periaortic fibrous mass that encases the ureters (causing obstructive uropathy), aorta, and inferior vena cava. Cardiac valve and pleural involvement follow the same mechanism. The drug holiday protocol — approximately 1 month off for every 5–6 months of treatment — was designed to interrupt the fibrotic stimulus at a stage where the early fibrous changes might partially regress before becoming irreversible structural fibrosis. The rationale was empirically derived from clinical observation rather than from a precise understanding of fibroblast remodeling kinetics, but the principle was sound: remove the 5-HT2B agonist stimulus periodically to allow fibrotic regression. Methysergide is no longer available in most countries because of this complication. Currently preferred prophylactic agents — topiramate, propranolol, valproate, amitriptyline, and CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) — achieve migraine prevention through entirely different mechanisms and carry no fibrotic liability.

• Option A: Option A is incorrect. Vasa vasorum vasoconstriction causing periaortic ischemia is not the established mechanism of methysergide-induced retroperitoneal fibrosis; the mechanism is 5-HT2B-mediated fibroblast activation by the methylergometrine metabolite. Ergotamine and DHE are not appropriate preventive agents and are not preferred alternatives to methysergide for this indication.
• Option B: Option B is incorrect. D2 receptor agonism on mesothelial cells suppressing prostaglandin E2 is not the established mechanism of methysergide fibrosis; while the list of preferred alternatives in Option B is largely correct, the mechanistic explanation is wrong.
• Option C: Option C is incorrect. 5-HT1B agonism on retroperitoneal lymphatic endothelium producing lymphedema is not the mechanism of methysergide fibrosis; triptans on a daily preventive basis are not recommended and do not share methysergide's 5-HT2B-mediated fibrosis risk.
• Option E: Option E is incorrect. Methysergide's primary mechanism is 5-HT2A/2C antagonism, not 5-HT2A agonism at retroperitoneal fibroblasts; and serotonin does not normally inhibit retroperitoneal fibroblast activity through 5-HT2A receptor activation. SSRIs are not recommended as migraine preventives and would not mitigate the fibrotic pathway through the mechanism described.